Melinda Manuel

In my current role, I am responsible for leading the strategic direction and execution of Drug Metabolism, Pharmacokinetics (DMPK), and Modeling efforts across the Gastrointestinal and Inflammation therapeutic areas. My portfolio spans early discovery through late-stage clinical development, where I guide DMPK strategies to ensure they align with the broader goals of the organization. This includes working closely with various internal stakeholders such as the Drug Discovery Unit, Clinical, and Regulatory teams to streamline our approach to drug development. A critical aspect of my role is overseeing the review and approval of preclinical pharmacokinetics data for regulatory submissions, including Investigational New Drug (IND) applications, New Drug Applications (NDA), Clinical Trial Applications (CTA), and related documents. I collaborate with cross-functional leadership to ensure submissions meet the highest scientific and regulatory standards. My strategic input shapes global DMPK practices and influences key organizational decisions aimed at advancing our pipeline. Additionally, I mentor a high-performing team of scientists. I emphasize a collaborative and innovative approach to problem-solving, ensuring the team is equipped to address complex scientific challenges. Through effective leadership, I have fostered a culture of continuous improvement, driving high-impact results while advancing cutting-edge therapies in fast-paced environments.

As Director, I led a diverse, multi-disciplinary team responsible for drug metabolism, pharmacokinetics, and modeling across the Gastrointestinal, Inflammation, and Neuroscience portfolios. My team integrated DMPK data into drug development strategies, applying advanced modeling techniques such as PKPD, PBPK, and mechanistic simulations to inform candidate selection and optimize clinical outcomes. These efforts ensured that DMPK considerations were embedded into key project decisions, helping drive successful development outcomes. A core focus of my role was fostering collaboration between project teams and senior management to ensure that DMPK strategies were well-aligned with the company's overall pipeline goals. I played a pivotal role in authoring and reviewing regulatory documents, contributing to the submission of pre-IND, IND, and INTERACT briefing books, all of which were essential for regulatory approvals. My ability to navigate complex regulatory environments ensured timely and successful submissions. In addition to my scientific responsibilities, I actively mentored DMPK Project Leads, providing strategic and scientific guidance to enhance the team's effectiveness. By fostering a culture of knowledge-sharing and continuous development, I empowered the team to take on greater scientific and strategic challenges, ultimately driving better decision-making for the therapeutic portfolios.

As Associate Director, I managed a portfolio of over 30 drug discovery and development projects across the Gastrointestinal and Neuroscience therapeutic areas. I provided strategic direction for each project, ensuring that DMPK efforts were well-integrated into overall development strategies. My role involved overseeing resource allocation, managing cross-functional collaborations, and driving project outcomes to ensure efficient progression from discovery through clinical phases. One of my key responsibilities was managing Vivarium Sciences personnel, who were responsible for conducting over 80 rodent PK studies annually. My leadership ensured high-quality data generation and ethical use of animal models, contributing to robust preclinical insights that supported candidate selection and regulatory submissions. I also played a central role in developing best practices for peptide therapeutics, a critical area of growth within Takeda. In addition to my operational duties, I authored and contributed to key regulatory submissions, including pre-IND and IND briefing books. These submissions were vital in ensuring timely approvals and advancing drug candidates through the pipeline. I also mentored junior scientists and project leads, helping develop their scientific and leadership skills to better support the organization’s evolving needs.

As Principal Scientist, I provided strategic oversight for the Motility portfolio, guiding over 10 drug discovery projects through the preclinical development phase. My expertise in DMPK and translational science allowed me to provide critical scientific input on resource planning, candidate characterization, and data integration to inform decision-making processes at key stages of development. I worked closely with cross-functional teams to ensure the effective application of DMPK data across projects. In my role as Nonclinical Research Project Lead, I led a multidisciplinary team of pharmacologists, toxicologists, and translational scientists, overseeing the early clinical development of a key asset targeting inflammatory diseases. Through collaborative efforts, we achieved early proof-of-concept and advanced the asset through the necessary regulatory milestones. This work highlighted my ability to lead cross-functional teams through complex scientific challenges while maintaining a clear focus on strategic goals. In addition to project-specific contributions, I was actively involved in global initiatives aimed at enhancing Takeda’s capabilities in biologics and diverse modalities. As Vice-chair of the Biologics and Diverse Modalities Center of Excellence, I was instrumental in establishing best practices and fostering a collaborative environment across research sites. This role allowed me to influence the strategic direction of biologics development at a global level.

In this role, I led cross-disciplinary teams consisting of medicinal chemists, pharmacologists, toxicologists, modelers, and clinicians. Together, we identified, optimized, and selected drug candidates with favorable DMPK profiles for further development. My responsibilities included the development of preclinical-to-clinical pharmacokinetic and pharmacodynamic (PKPD) strategies, ensuring that candidates were well-positioned for success in early clinical studies. A key focus of my work was applying advanced pharmacokinetic modeling techniques, including allometric scaling, compartmental modeling, and PKPD simulations, to predict human PK and support the design of First-In-Human (FIH) and Phase 2 clinical trials. These efforts contributed to more informed dose selection and improved clinical trial outcomes. Additionally, I developed and validated quantitative biomarker assays, enabling the prediction of efficacious human doses and guiding the design of clinical trials. I also introduced new technical capabilities, such as SIMOA and immune-capture LC-MS/MS platforms, significantly enhancing our ability to support complex biomarker analyses across a broad range of therapeutic programs.

As Staff Scientist, I established and led a specialized bioanalytical team focused on large molecule biotherapeutic programs. My team was responsible for developing and executing strategies to support the preclinical and clinical development of biologics, providing critical pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity data necessary for advancing drug candidates. I played a key role in driving innovation within the bioanalytical group, particularly in the development and validation of novel biomarker assays using advanced technologies such as LC-MS/MS. These assays provided critical data for characterizing drug candidates, informing decision-making at key stages of development, and supporting regulatory submissions. Additionally, I managed relationships with external Contract Research Organizations (CROs), ensuring that all Good Laboratory Practice (GLP) and Good Clinical Practice (GxP) bioanalytical work met the highest regulatory and scientific standards. My contributions helped significantly expand the bioanalytical capabilities of the team, enabling more efficient and effective support for a growing portfolio of biologics.

As an Associate Scientist, I was responsible for developing and validating in vitro ADME (absorption, distribution, metabolism, and excretion) assays and biomarker methods to support drug candidate progression. I played a key role in developing multiple quantitative biomarker assays that informed pharmacokinetic and pharmacodynamic models, contributing to the design and execution of clinical trials. I also led efforts to optimize bottom-up high-resolution mass spectrometry proteomics techniques for pathway analysis and biomarker discovery, enabling the identification of key biomarkers for drug efficacy and safety. Additionally, I developed Time-Dependent Inhibition assays to assess drug-drug interaction potential, providing critical data for lead candidate selection. In this role, I worked closely with multidisciplinary teams across the organization to ensure the seamless integration of ADME data into decision-making processes. My efforts contributed to the successful advancement of numerous drug candidates through the preclinical development pipeline.

In this role, I developed and validated in vitro ADME assays, including microsomal stability, hepatocyte stability, and plasma protein binding studies, to support the progression of clinical candidates. My work provided critical data for candidate selection and optimization, contributing to the overall success of drug development programs. I also played a key role in automating high-throughput ADME assays, which significantly increased the efficiency and throughput of early-stage drug development processes. In addition to my scientific responsibilities, I supervised and mentored junior associates and interns, providing guidance on in vitro ADME assays, liquid handling, and good documentation practices.

As a Senior Research Associate, I optimized the throughput of several key in vitro ADME assays, enabling faster decision-making on drug programs. My work involved performing metabolic stability and plasma protein binding studies for a wide range of clinical candidates, contributing to the selection and progression of lead compounds. I also supervised two year-round interns, mentoring them on the development and validation of ADME assays, liquid handling techniques, and mass spectrometry analysis. My mentorship helped build the next generation of scientific talent while ensuring high-quality data generation across multiple programs.

In this role, I was responsible for developing and executing hepatocyte stability assays, as well as performing LC-MS/MS analysis for screening in drug discovery. My focus was on evaluating Phase I and Phase II metabolite formation to identify chemical liabilities, contributing to improved drug design and selection. I played a key role in developing an open-access LC-MS system for protein deconvolution, supporting quality control for proteins used in structure-based drug design. Additionally, I maintained the LC-MS and HPLC systems used at the site, ensuring optimal performance for critical analytical processes.

As a Research Associate, I supported structure-based drug design by utilizing a variety of extraction and purification techniques to prepare proteins for crystallization. I was responsible for maintaining the suite of HPLC purification equipment and optimizing purification protocols, ensuring high-quality, high-yield protein preparations. My contributions helped advance critical drug design programs, providing the analytical support needed for the identification and validation of new therapeutic targets.

At The Scripps Research Institute, I executed complex purification processes for catalytic and therapeutic monoclonal antibodies and target proteins. My work involved performing sterile fusion of murine myeloma and spleen cells, followed by antibody titer analysis using ELISA to ensure high-quality antibody production. I also trained and mentored research staff in the operation and maintenance of AKTA-Prime systems for protein purification. This helped improve laboratory efficiency and enhanced the overall quality of purified proteins used in research and development programs.

In this role, I developed and optimized protocols for antibody purification using techniques such as SAS precipitation, affinity chromatography, and ion exchange chromatography. These efforts resulted in the high-yield, high-purity antibody preparations necessary for advancing therapeutic research. My contributions included RNA extraction from various cell lines and radiolabeling of cDNA probes for antibacterial discovery. I also played a role in amplifying cDNA from bacteriophage plaques, supporting the early stages of therapeutic research.

At MARDX, I was responsible for conducting disease-specific Western Blot and ELISA assays according to Standard Operating Procedures (SOPs) and Good Manufacturing Practices (GMPs). My work ensured the accuracy and reliability of diagnostic products, which were used in various medical settings. I also performed stability studies on diagnostic products, meticulously reviewing and documenting results to ensure compliance with regulatory standards and product specifications. My attention to detail contributed to the overall quality and reliability of MARDX’s diagnostic portfolio.